Immunotherapy in Non-small Cell Lung Cancer: a Review

Detalhes bibliográficos
Autor(a) principal: Sequeira, Telma
Data de Publicação: 2023
Outros Autores: Almodovar, M. Teresa
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.48729/pjctvs.371
Resumo: Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy are not fully understood, and ongoing research aims to overcome these challenges. In the early-stage setting, neoadjuvant and adjuvant trials are investigating the efficacy of ICIs in combination with chemotherapy, with interesting results. Additionally, in the metastatic landscape of NSCLC the therapeutic options multiplied in recent years. The use of immunotherapy in NSCLC holds great promise, and future studies may provide more effective therapies and biomarkers for personalized treatment approaches.
id RCAP_9578b0443985085a7d7b75cb2409883f
oai_identifier_str oai:oai.pjctvs.com:article/371
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Immunotherapy in Non-small Cell Lung Cancer: a ReviewimmunotherapyNSCLCtreatmentlung cancerimmune checkpoint inhibitorsImmunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy are not fully understood, and ongoing research aims to overcome these challenges. In the early-stage setting, neoadjuvant and adjuvant trials are investigating the efficacy of ICIs in combination with chemotherapy, with interesting results. Additionally, in the metastatic landscape of NSCLC the therapeutic options multiplied in recent years. The use of immunotherapy in NSCLC holds great promise, and future studies may provide more effective therapies and biomarkers for personalized treatment approaches.SOCIEDADE PORTUGUESA DE CIRURGIA CARDIO-TORÁCICA E VASCULAR2023-10-11info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.48729/pjctvs.371https://doi.org/10.48729/pjctvs.371Portuguese Journal of Cardiac Thoracic and Vascular Surgery; Vol. 30 No. 3 (2023): Jul-Sep; 55-652184-9927reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttps://pjctvs.com/index.php/journal/article/view/371https://pjctvs.com/index.php/journal/article/view/371/333Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgeryinfo:eu-repo/semantics/openAccessSequeira, TelmaAlmodovar, M. Teresa2023-10-21T04:52:54Zoai:oai.pjctvs.com:article/371Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:35:37.383835Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Immunotherapy in Non-small Cell Lung Cancer: a Review
title Immunotherapy in Non-small Cell Lung Cancer: a Review
spellingShingle Immunotherapy in Non-small Cell Lung Cancer: a Review
Sequeira, Telma
immunotherapy
NSCLC
treatment
lung cancer
immune checkpoint inhibitors
title_short Immunotherapy in Non-small Cell Lung Cancer: a Review
title_full Immunotherapy in Non-small Cell Lung Cancer: a Review
title_fullStr Immunotherapy in Non-small Cell Lung Cancer: a Review
title_full_unstemmed Immunotherapy in Non-small Cell Lung Cancer: a Review
title_sort Immunotherapy in Non-small Cell Lung Cancer: a Review
author Sequeira, Telma
author_facet Sequeira, Telma
Almodovar, M. Teresa
author_role author
author2 Almodovar, M. Teresa
author2_role author
dc.contributor.author.fl_str_mv Sequeira, Telma
Almodovar, M. Teresa
dc.subject.por.fl_str_mv immunotherapy
NSCLC
treatment
lung cancer
immune checkpoint inhibitors
topic immunotherapy
NSCLC
treatment
lung cancer
immune checkpoint inhibitors
description Immunotherapy has revolutionized the field of oncology by utilizing the body's immune system to target and eliminate cancer cells. In non-small cell lung cancer (NSCLC), immunotherapeutic agents such as immune checkpoint inhibitors (ICIs) have shown promising results. ICIs target receptors like PD-1, PD-L1, and CTLA-4 to enhance the immune response against tumors. However, resistance mechanisms to immunotherapy are not fully understood, and ongoing research aims to overcome these challenges. In the early-stage setting, neoadjuvant and adjuvant trials are investigating the efficacy of ICIs in combination with chemotherapy, with interesting results. Additionally, in the metastatic landscape of NSCLC the therapeutic options multiplied in recent years. The use of immunotherapy in NSCLC holds great promise, and future studies may provide more effective therapies and biomarkers for personalized treatment approaches.
publishDate 2023
dc.date.none.fl_str_mv 2023-10-11
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.48729/pjctvs.371
https://doi.org/10.48729/pjctvs.371
url https://doi.org/10.48729/pjctvs.371
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://pjctvs.com/index.php/journal/article/view/371
https://pjctvs.com/index.php/journal/article/view/371/333
dc.rights.driver.fl_str_mv Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Portuguese Journal of Cardiac Thoracic and Vascular Surgery
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv SOCIEDADE PORTUGUESA DE CIRURGIA CARDIO-TORÁCICA E VASCULAR
publisher.none.fl_str_mv SOCIEDADE PORTUGUESA DE CIRURGIA CARDIO-TORÁCICA E VASCULAR
dc.source.none.fl_str_mv Portuguese Journal of Cardiac Thoracic and Vascular Surgery; Vol. 30 No. 3 (2023): Jul-Sep; 55-65
2184-9927
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133619221954560

Registros relacionados